- Home
- MKZR vs LYRA Comparison
MKZR vs LYRA Comparison
Compare MKZR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | LYRA |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MKZR | LYRA |
|---|---|---|
| Price | $3.75 | $3.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 41.8K | ★ 92.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 26.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,994,778.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $3.26 | $2.84 |
| 52 Week High | $50.00 | $37.50 |
Technical Indicators
Market Signals| Indicator | MKZR | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 40.59 |
| Support Level | $3.65 | $3.55 |
| Resistance Level | $5.00 | $4.25 |
| Average True Range (ATR) | 0.44 | 0.40 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 19.77 | 17.63 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.